Clinical trials
Atrial Fibrillation trials in Russia with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 2 |
| 2013 | 4 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 1 |
| 2021 | 2 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 23 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Meshalkin Research Institute of Pathology of Circulation | 14 |
| Research Institute for Complex Problems of Cardiovascular Diseases, Russia | 2 |
| Center for Strategic Planning, of the Federal Medical and Biological Agency | 1 |
| Erasmus Medical Center | 1 |
| Ettore Sansavini Health Science Foundation | 1 |
| Federal Research Clinical Center of Federal Medical & Biological Agency, Russia | 1 |
| Irina Ermolaeva | 1 |
| National Research Center of Surgery, Russia | 1 |
| Ural State Medical University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Atrial Fibrillation | 23 |
| Coronary Artery Disease | 2 |
| Myocardial Ischemia | 2 |
| Atherosclerosis | 1 |
| Coronary Disease | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Heart Diseases | 1 |
| Hypertension | 1 |
| Hypertension, Pulmonary | 1 |
| Mitral Valve Insufficiency | 1 |
Trials
Showing 1 to 23 of 23. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.